Presbyopia Epidemiology Forecast

DelveInsight’s ‘Presbyopia - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Presbyopia Disease Understanding

Presbyopia is a normal part of aging wherein your eyes gradually lose the ability to see things up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after the age of 40 as the lenses of the eyes naturally lose their elasticity due to the aging process.

 

It is mostly due to age-related changes that the proteins within the lens of the eye become thicker, harder, and less flexible. This loss of flexibility affects the lens's ability to refract light rays which, in turn, affects the eye's capacity to focus. Age is the major risk factor for the development of presbyopia along with factors like trauma, systemic disease, cardiovascular disease, or a drug side effect. According to type, Presbyopia can be classified into incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia

 

Initial symptoms include difficulties with prolonged close-up work along with tiring of the eyes. Other common symptoms are delays in focusing at near or distance, ocular discomfort, headache, asthenopia, squinting, fatigue or drowsiness from near work, increased working distance, need for brighter light for reading, and diplopia. This may progress to blurred vision when looking at objects close up and to headaches and eye strain when attempting close work

 

Presbyopia Diagnosis

A basic and comprehensive examination of the eye with a series of different tests is necessary to diagnose presbyopia. The ophthalmologist examines the retina and conducts muscle integrity, refraction, slit-lamp, visual field, and visual acuity tests. These will help to ascertain the condition. Eye drops used during this process to dilate the pupils will cause patients to experience increased sensitivity to light in the few hours following the examinations.

 

With the help of an ophthalmoscope, the specialist can evaluate the retina, optic disk, and choroid (i.e. a layer of blood vessels responsible for providing nourishment to the retina). A muscle integrity test is done with a moving object, and the ability to follow this object is evaluated. Refractive tests assess how well light waves are bent as they go through the cornea and the lens and the results of these tests help to determine which lens prescription will be needed. However, Presbyopia cannot be prevented as it is an inevitable part of aging.

Continued in the report…..

Presbyopia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Presbyopia, total diagnosed cases of Presbyopia, total age-specific cases of Presbyopia, gender-specific cases of Presbyopia, and severity-specific cases of Presbyopia scenario of Presbyopia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Presbyopia Detailed Epidemiology Segmentation

  • Total prevalent cases of Presbyopia in the 7MM were found to be 289,136,235 cases in 2021. These cases are expected to change by 2032 at a CAGR of 1.4% during the study period (2019–2032).
  • Among 7MM, the United States has the highest number of prevalent cases of Presbyopia with 118,346,762 cases in 2021.
  • Assessments as per DelveInsight’s analysts show that in 2021, in the United States, the severity-specific cases of Presbyopia were 20,301,021 and 81,204,086 for mild cases and moderate to severe cases, respectively which are expected to rise significantly by 2032.
  • In the US, the total age-specific cases of Presbyopia were 28,859,295, 33,190,032, 24,012,555, and  15,443,224 cases for the age group less than 60 years, 60–69 years, 70–79 years, and ≥80 years respectively, in the year 2021. These cases are expected to rise significantly by 2032.
  • In EU-5, Germany had the highest prevalent population of Presbyopia with  36,822,212 cases, followed by Italy with  27,683,651 cases in 2021. On the other hand, Spain had the lowest prevalent population for 2021.
  • In 2021, Japan had 34,568,372 total prevalent cases of Presbyopia.

Scope of the Report

  • The report covers the descriptive overview of Presbyopia, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of Presbyopia.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM, a total number of prevalent cases of Presbyopia, severity-specific cases of Presbyopia, and prevalent cases of Presbyopia by risk factors.

Report Highlights

  • 11-Year Forecast of Presbyopia
  • The 7MM Coverage
  • Total prevalent cases of Presbyopia
  • Total diagnosed cases of Presbyopia
  • Total age-specific cases of Presbyopia
  • Gender-specific cases of Presbyopia
  • Severity-specific Cases of Presbyopia

Key Questions Answered

  • What are the disease risk and burdens of Presbyopia?
  • What is the historical Presbyopia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Presbyopia at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population with Presbyopia?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Presbyopia during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy

The Presbyopia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Presbyopia epidemiology forecast.
  • The Presbyopia epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
  • The Presbyopia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboPresbyopia, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Presbyopia Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Presbyopia in 2019

3.2. Patient Share (%) Distribution of Presbyopia in 2032

4. Executive Summary of Presbyopia

5. Disease Background and Overview

5.1. Introduction

5.1.1. Signs and Symptoms of Presbyopia

5.1.2. Difference between Presbyopia and Hyperopia

5.1.3. Risk Factors and Causes of Presbyopia

5.1.4. Pathophysiology of Presbyopia

5.1.5. Complications of Presbyopia

6. Diagnosis of Presbyopia

6.1. Patient History

6.2. Ocular Examination

6.2.1. Visual Acuity

6.2.2. Keratometry/Topography

6.2.3. Refraction

6.2.4. Binocular Vision and Accommodation

6.3. Supplemental Testing

6.4. Eye health evaluation

7. Recommended eye examination frequency for pediatric patients and adults

8. Differential Diagnosis

9. Early Detection and Prevention of Presbyopia

10. Epidemiology and Patient Population

10.1. Key Findings

10.2. Methodology of Epidemiology

10.3. Assumptions and Rationale: 7MM

10.4. Total Prevalent Cases of Presbyopia in the 7MM

10.5. The United States

10.5.1. Total Prevalent Cases of Presbyopia in the US

10.5.2. Total Diagnosed Cases of Presbyopia in the US

10.5.3. Total Age-specific Cases of Presbyopia in the US

10.5.4. Gender-specific Cases of Presbyopia in the US

10.5.5. Severity-specific Cases of Presbyopia in the US

10.6. EU-5 Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

10.6.1. Germany

10.6.1.1. Total Prevalent Cases of Presbyopia in Germany

10.6.1.2. Total Diagnosed Cases of Presbyopia in Germany

10.6.1.3. Total Age-specific Cases of Presbyopia in Germany

10.6.1.4. Gender-specific Cases of Presbyopia in Germany

10.6.1.5. Severity-specific Cases of Presbyopia in Germany

10.6.2. France

10.6.2.1. Total Prevalent Cases of Presbyopia in France

10.6.2.2. Total Diagnosed Cases of Presbyopia in France

10.6.2.3. Total Age-specific Cases of Presbyopia in France

10.6.2.4. Gender-specific Cases of Presbyopia in France

10.6.2.5. Severity-specific Cases of Presbyopia in France

10.6.3. Italy

10.6.3.1. Total Prevalent Cases of Presbyopia in Italy

10.6.3.2. Total Diagnosed Cases of Presbyopia in Italy

10.6.3.3. Total Age-specific Cases of Presbyopia in Italy

10.6.3.4. Gender-specific Cases of Presbyopia in Italy

10.6.3.5. Severity-specific Cases of Presbyopia in Italy

10.6.4. Spain

10.6.4.1. Total Prevalent Cases of Presbyopia in Spain

10.6.4.2. Total Diagnosed Cases of Presbyopia in Spain

10.6.4.3. Total Age-specific Cases of Presbyopia in Spain

10.6.4.4. Gender-specific Cases of Presbyopia in Spain

10.6.4.5. Severity-specific Cases of Presbyopia in Spain

10.6.5. The United Kingdom

10.6.5.1. Total Prevalent Cases of Presbyopia in the UK

10.6.5.2. Total Diagnosed Cases of Presbyopia in the UK

10.6.5.3. Total Age-specific Cases of Presbyopia in the UK

10.6.5.4. Gender-specific Cases of Presbyopia in the UK

10.6.5.5. Severity-specific Cases of Presbyopia in the UK

10.7. Japan

10.7.1. Total Prevalent Cases of Presbyopia in Japan

10.7.2. Total Diagnosed Cases of Presbyopia in Japan

10.7.3. Total Age-specific Cases of Presbyopia in Japan

10.7.4. Gender-specific Cases of Presbyopia in Japan

10.7.5. Severity-specific Cases of Presbyopia in Japan

11. Patient Journey

12. KOL Views

13. Appendix

13.1. Bibliography

13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

Table 1: Summary of Presbyopia Epidemiology (2019–2032)

Table 2: Common risk factors of presbyopia

Table 3: Recommended examination frequency for the pediatric patient

Table 4: Recommended examination frequency for the adult patient

Table 5: Comparison of the diagnosis guidelines

Table 6: Total Prevalent Cases of Presbyopia in the 7MM (2019–2032)

Table 7: Total Prevalent Cases of Presbyopia in the United States (2019–2032)

Table 8: Total Diagnosed Cases of Presbyopia in the United States (2019–2032)

Table 9: Total Age-specific Cases of Presbyopia in the United States (2019–2032)

Table 10: Gender-specific Cases of Presbyopia in the United States (2019–2032)

Table 11: Severity-specific Cases of Presbyopia in the United States (2019–2032)

Table 12: Total Prevalent Cases of Presbyopia in Germany (2019–2032)

Table 13: Total Diagnosed Cases of Presbyopia in Germany (2019–2032)

Table 14: Total Age-specific Cases of Presbyopia in Germany (2019–2032)

Table 15: Gender-specific Cases of Presbyopia in Germany (2019–2032)

Table 16: Severity-specific Cases of Presbyopia in Germany (2019–2032)

Table 17: Total Prevalent Cases of Presbyopia in France (2019–2032)

Table 18: Total Diagnosed Cases of Presbyopia in France (2019–2032)

Table 19: Total Age-specific Cases of Presbyopia in France (2019–2032)

Table 20: Gender-specific Cases of Presbyopia in France (2019–2032)

Table 21: Severity-specific Cases of Presbyopia in France (2019–2032)

Table 22: Total Prevalent Cases of Presbyopia in Italy (2019–2032)

Table 23: Total Diagnosed Cases of Presbyopia in Italy (2019–2032)

Table 24: Total Age-specific Cases of Presbyopia in Italy (2019–2032)

Table 25: Gender-specific Cases of Presbyopia in Italy (2019–2032)

Table 26: Severity-specific Cases of Presbyopia in Italy (2019–2032)

Table 27: Total Prevalent Cases of Presbyopia in Spain (2019–2032)

Table 28: Total Diagnosed Cases of Presbyopia in Spain (2019–2032)

Table 29: Total Age-specific Cases of Presbyopia in Spain (2019–2032)

Table 30: Gender-specific Cases of Presbyopia in Spain (2019–2032)

Table 31: Severity-specific Cases of Presbyopia in Spain (2019–2032)

Table 32: Total Prevalent Cases of Presbyopia in the United Kingdom (2019–2032)

Table 33: Total Diagnosed Cases of Presbyopia in the United Kingdom (2019–2032)

Table 34: Total Age-specific Cases of Presbyopia in the United Kingdom (2019–2032)

Table 35: Gender-specific Cases of Presbyopia in the United Kingdom (2019–2032)

Table 36: Severity-specific Cases of Presbyopia in the United Kingdom (2019–2032)

Table 37: Total Prevalent Cases of Presbyopia in Japan (2019–2032)

Table 38: Total Diagnosed Cases of Presbyopia in Japan (2019–2032)

Table 39: Total Age-specific Cases of Presbyopia in Japan (2019–2032)

Table 40: Gender-specific Cases of Presbyopia in Japan (2019–2032)

Table 41: Severity-specific Cases of Presbyopia in Japan (2019–2032)

List of Figures

Figure 1: Epidemiology Methodology

Figure 2: Presbyopia compared to a Normal eye

Figure 3: Symptoms of Presbyopia

Figure 4: Causes of Presbyopia

Figure 5: Anatomy of the eye

Figure 6: Pathogenesis of Presbyopia

Figure 7: Differential diagnosis of presbyopia

Figure 8: Total Prevalent Cases of Presbyopia in the 7MM (2019–2032)

Figure 9: Total Prevalent Cases of Presbyopia in the United States (2019–2032)

Figure 10: Total Diagnosed Cases of Presbyopia in the United States (2019–2032)

Figure 11: Total Age-specific Cases of Presbyopia in the United States (2019–2032)

Figure 12: Gender-specific Cases of Presbyopia in the United States (2019–2032)

Figure 13: Severity-specific Cases of Presbyopia in the United States (2019–2032)

Figure 14: Total Prevalent Cases of Presbyopia in Germany (2019–2032)

Figure 15: Total Diagnosed Cases of Presbyopia in Germany (2019–2032)

Figure 16: Total Age-specific Cases of Presbyopia in Germany (2019–2032)

Figure 17: Gender-specific Cases of Presbyopia in Germany (2019–2032)

Figure 18: Severity-specific Cases of Presbyopia in Germany (2019–2032)

Figure 19: Total Prevalent Cases of Presbyopia in France (2019–2032)

Figure 20: Total Diagnosed Cases of Presbyopia in France (2019–2032)

Figure 21: Total Age-specific Cases of Presbyopia in France (2019–2032)

Figure 22: Gender-specific Cases of Presbyopia in France (2019–2032)

Figure 23: Severity-specific Cases of Presbyopia in France (2019–2032)

Figure 24: Total Prevalent Cases of Presbyopia in Italy (2019–2032)

Figure 25: Total Diagnosed Cases of Presbyopia in Italy (2019–2032)

Figure 26: Total Age-specific Cases of Presbyopia in Italy (2019–2032)

Figure 27: Gender-specific Cases of Presbyopia in Italy (2019–2032)

Figure 28: Severity-specific Cases of Presbyopia in Italy (2019–2032)

Figure 29: Total Prevalent Cases of Presbyopia in Spain (2019–2032)

Figure 30: Total Diagnosed Cases of Presbyopia in Spain (2019–2032)

Figure 31: Total Age-specific Cases of Presbyopia in Spain (2019–2032)

Figure 32: Gender-specific Cases of Presbyopia in Spain (2019–2032)

Figure 33: Severity-specific Cases of Presbyopia in Spain (2019–2032)

Figure 34: Total Prevalent Cases of Presbyopia in the United Kingdom (2019–2032)

Figure 35: Total Diagnosed Cases of Presbyopia in the United Kingdom (2019–2032)

Figure 36: Total Age-specific Cases of Presbyopia in the United Kingdom (2019–2032)

Figure 37: Gender-specific Cases of Presbyopia in the United Kingdom (2019–2032)

Figure 38: Severity-specific Cases of Presbyopia in the United Kingdom (2019–2032)

Figure 39: Total Prevalent Cases of Presbyopia in Japan (2019–2032)

Figure 40: Total Diagnosed Cases of Presbyopia in Japan (2019–2032)

Figure 41: Total Age-specific Cases of Presbyopia in Japan (2019–2032)

Figure 42: Gender-specific Cases of Presbyopia in Japan (2019–2032)

Figure 43: Severity-specific Cases of Presbyopia in Japan (2019–2032)

Figure 44: Patient Journey

Forward to Friend

Need A Quote